Patent Expiries Driving the Growth in Cancer Generic Drugs

The global cancer generics market is expected to advance significantly with patent expiries of leading blockbuster drugs playing a leading role, says RNCOS.

NOIDA, India (prHWY.com) August 30, 2012 - According to a new report by RNCOS, "Cancer Generics Market Analysis", the global cancer generics market is one of the most attractive segments among all the therapeutic classes in the generic drugs industry. Despite accounting for a miniscule share of overall oncology market, cancer generics are effectively heading towards a significant growth pattern. Factors such as burgeoning healthcare cost and patent expiries are expected to drive a healthy CAGR of around 26% in the overall market during 2011-2015.

As per the report, patent expiries of blockbuster oncology drugs will prove as the major and prominent factor in the future growth of cancer generics. Drugs, such as Avastin, Alimta, Vectibix among others are likely to go off patent in the coming decade, hence opening billions of market potential for cancer generics players. Currently, players are ready to tap the market by developing generics for various types of cancer on the same manufacturing line as their branded versions.

The report, "Cancer Generics Market Analysis", effectively provides an insight into the global cancer generics market through proper analysis of drivers, restraints and key developments. It evaluates the current status and future potential of generic drugs in most common cancers worldwide, such as lung cancer, breast cancer, colon cancer, stomach cancer, and prostate cancer. A brief overview of oral and injectable generics has also been provided in the extensive study that aims at presenting an impartial picture of the market to clients.

The report covers all the key aspects of the global cancer generics market, including the competitive landscape that discusses profiles of leading players like Hospira and Accord Healthcare. Overall, the report is an optimum source of knowledge and statistics for the clients interested to enter or expand in cancer generics market.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM353.htm

Some of our Related Reports are:

- Japan Generics Market Analysis (http://www.rncos.com/Report/IM371.htm)
- Generic Drug Market in Canada (http://www.rncos.com/Report/IM598.htm)
- Booming Generics Drug Market in India (http://www.rncos.com/Report/IM256.htm)
- UK Generics Market Analysis (http://www.rncos.com/Report/IM313.htm)
- Booming US Generic Drug Market (http://www.rncos.com/Report/IM589.htm)

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

About RNCOS

RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals analyze the industry and its various components, with a comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the intending consultants in meeting their objectives in a cost-effective and timely manner.

###

Tag Words: cancer incidences

Categories: Health

Press Release Contact
B-129, Sector 6 Noida - 201301
91-120-4224-700
91-120-4224-707

Link To This Press Release:

URL HTML Code